Acurx Pharmaceuticals Q2 loss widens on higher R&D costs

Acurx Pharmaceuticals

14/08/2026 12:11

Overview
US biopharmaceutical developer's Q2 net loss per share widened yr/yr
Company ended Q2 with $10.7 mln cash, boosted by direct offering and equity line
R&D expenses increased due to manufacturing and consulting costs for new clinical trial

Outlook
Company did not provide specific financial guidance for the current or future periods

Result Drivers
R&D SPENDING - Higher research and development expenses driven by increased manufacturing and consulting costs for new recurrent CDI trial program
LOWER G&A COSTS - Decrease in general and administrative expenses mainly due to reduced professional fees, legal costs, and share-based compensation

Company press release: ID:nPn4Jg5RYa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.53
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Acurx Pharmaceuticals Inc is $10.00, about 575.7% above its August 13 closing price of $1.48

Reuters Recommended Reads
Aug 12 - Turn Therapeutics Q2 net loss per share widens on higher R&D costs
Aug 13 - Ensysce Biosciences Q2 net loss widens on higher R&D costs
Aug 13 - Kodiak Sciences Q2 net loss widens on higher R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)